Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
H. J. Einolf. (2007) Comparison of different approaches to predict metabolic drug–drug interactions. Xenobiotica 37:10-11, pages 1257-1294.
Read now
Read now
Articles from other publishers (29)
Eman El‐Khateeb, Adam S. Darwich, Brahim Achour, Varinder Athwal & Amin Rostami‐Hodjegan. (2021) Review article: time to revisit Child‐Pugh score as the basis for predicting drug clearance in hepatic impairment. Alimentary Pharmacology & Therapeutics 54:4, pages 388-401.
Crossref
Crossref
Sibylle Neuhoff & Geoffrey T. Tucker. (2018) Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?. British Journal of Clinical Pharmacology 84:7, pages 1620-1621.
Crossref
Crossref
Sharon I. Igbinoba, Cyprian O. Onyeji, Moses A. Akanmu, Julius O. Soyinka, Srirama Sarma V.V. Pullela, James M. Cook & Thomas I. Nathaniel. (2015)
Effect of dehusked
Garcinia kola
seeds on the overall pharmacokinetics of quinine in healthy Nigerian volunteers
. The Journal of Clinical Pharmacology 55:3, pages 348-354.
Crossref
Crossref
Daniel T. Barratt, Benedikte Bandak, Pål Klepstad, Ola Dale, Stein Kaasa, Lona L. Christrup, Jonathan Tuke & Andrew A. Somogyi. (2014) Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics 24:4, pages 185-194.
Crossref
Crossref
Vidya Perera, Annette S. Gross, Alan Forrest, Cornelia B. Landersdorfer, Hongmei Xu, Sihem Ait-Oudhia & Andrew J. McLachlan. (2013) A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity. Drug Metabolism and Disposition 41:11, pages 1957-1966.
Crossref
Crossref
Lewis Couchman, Sally V.J. Bowskill, Simon Handley, Maxine X. Patel & Robert J. Flanagan. (2013) Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010. Early Intervention in Psychiatry 7:2, pages 122-130.
Crossref
Crossref
Katarina Ilic, Roy L. Hawke, Ranjit K. Thirumaran, Erin G. Schuetz, J. Heyward Hull, Angela D.M. Kashuba, Paul W. Stewart, Celeste M. Lindley & Mei-Ling Chen. (2013)
The Influence of Sex, Ethnicity, and
CYP2B6
Genotype on Bupropion Metabolism as an Index of Hepatic CYP2B6 Activity in Humans
. Drug Metabolism and Disposition 41:3, pages 575-581.
Crossref
Crossref
Eloise A. Gelston, Janet K. Coller, Olga V. Lopatko, Heather M. James, Helmut Schmidt, Jason M. White & Andrew A. Somogyi. (2012) Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology 73:5, pages 786-794.
Crossref
Crossref
Joseph Bloom, Anthony L. Hinrichs, Jen C. Wang, Linda B. von Weymarn, Evan D. Kharasch, Laura J. Bierut, Alison Goate & Sharon E. Murphy. (2011) The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European–Americans. Pharmacogenetics and Genomics 21:7, pages 403-416.
Crossref
Crossref
Maurice J. Ahsman, Dick Tibboel, Ron A. A. Mathot & Saskia N. de Wildt. 2011. Pediatric Clinical Pharmacology. Pediatric Clinical Pharmacology
203
217
.
Saskia N. de Wildt, Greg L. Kearns, Darryl J. Murry, Gideon Koren & John N. van den Anker. (2009) Ontogeny of midazolam glucuronidation in preterm infants. European Journal of Clinical Pharmacology 66:2, pages 165-170.
Crossref
Crossref
Sabrina Peterson, Yvonne Schwarz, Shuying S. Li, Lin Li, Irena B. King, Chu Chen, David L. Eaton, John D. Potter & Johanna W. Lampe. (2009)
CYP1A2, GSTM1
, and
GSTT1
Polymorphisms and Diet Effects on CYP1A2 Activity in a Crossover Feeding Trial
. Cancer Epidemiology, Biomarkers & Prevention 18:11, pages 3118-3125.
Crossref
Crossref
Sussan Ghassabian, Manoranjenni Chetty, Bruce N Tattam, MRACI C Chem, John Glen, Jeannie Rahme, Zvijezdana Stankovic, Iqbal Ramzan, Michael Murray & Andrew J McLachlan. (2009) A High-Throughput Assay Using Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous In Vivo Phenotyping of 5 Major Cytochrome P450 Enzymes in Patients. Therapeutic Drug Monitoring 31:2, pages 239-246.
Crossref
Crossref
Saskia N. de Wildt, Shinya Ito & Gideon Koren. (2009) Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discovery Today 14:1-2, pages 6-15.
Crossref
Crossref
Evan D. Kharasch, Darain Mitchell & Rebecka Coles. (2008) Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity. The Journal of Clinical Pharmacology 48:4, pages 464-474.
Crossref
Crossref
Sabrina Peterson, Johanna W. Lampe, Theo K. Bammler, Kerstin Gross-Steinmeyer & David L. Eaton. (2006) Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food and Chemical Toxicology 44:9, pages 1474-1484.
Crossref
Crossref
Koichi Yokogawa, Akane Ido, Takeshi Kurihara, Yasunari Mano, Masaaki Nomura, Junko Ishizaki & Ken-ichi Miyamoto. (2006) Serum Aminotransferase Activity as a Predictor for Estimation of Total Clearance of Hepatically Metabolized Drugs in Rats with Acute Hepatic Failure. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 29:1, pages 141-145.
Crossref
Crossref
Mirko S. Faber, Alexander Jetter & Uwe Fuhr. (2005) Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 97:3, pages 125-134.
Crossref
Crossref
Mahmut Özdemir, Kim H. Crewe, Geoffrey T. Tucker & Amin Rostami-Hodjegan. (2004) Assessment of In Vivo CYP2D6 Activity: Differential Sensitivity of Commonly Used Probes to Urine pH. The Journal of Clinical Pharmacology 44:12, pages 1398-1404.
Crossref
Crossref
Á Nyéki, T. Buclin, J. Biollaz & L. A. Decosterd. (2003) NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. British Journal of Clinical Pharmacology 55:1, pages 62-67.
Crossref
Crossref
Jooran S. Kim, Anne N. Nafziger, Shirley M. Tsunoda, Edna F. Choo, Daniel S. Streetman, Angela D. M. Kashuba, Robert W. Kulawy, Debra J. Beck, Mario L. RocciJr.Jr., Grant R. Wilkinson, David J. Greenblatt & Joseph S. BertinoJr.Jr.. (2013) Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. The Journal of Clinical Pharmacology 42:4, pages 376-382.
Crossref
Crossref
David Lewis. 2001. Guide to Cytochromes P450. Guide to Cytochromes P450
164
210
.
Daniel S. Streetman, Angela D. M. Kashuba, Joseph S. BertinoJrJr, Robert Kulawy, Mario L. RocciJrJr & Anne N. Nafziger. (2001) Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. Pharmacogenetics 11:4, pages 349-355.
Crossref
Crossref
M AM Wenkerl, S Kežić, A C Monster & F A de Wolff. (2016) Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. Human & Experimental Toxicology 20:5, pages 221-228.
Crossref
Crossref
Maurice Dickins & Geoff Tucker. (2001) International Journal of Pharmaceutical Medicine 15:2, pages 70-73.
Crossref
Crossref
Maurice Dickins & Geoff Tucker. (2001) Drug disposition: to phenotype orgenotype. International Journal of Pharmaceutical Medicine 15:2, pages 70-73.
Crossref
Crossref
Line Labbe, Caroline Sirois, Sylvie Pilote, Marie Arseneault, N. Robitaille, Jacques Turgeon & Bettina Hamelin. (2000) Pharmacogenetics 10:5, pages 425-438.
Crossref
Crossref
Daniel S. Streetman, Joseph S. BertinoJrJr & Anne N. Nafziger. (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:3, pages 187-216.
Crossref
Crossref
Geoffrey T. Tucker. (2000) Advances in Understanding Drug Metabolism and Its Contribution to Variability in Patient Response. Therapeutic Drug Monitoring 22:1, pages 110-113.
Crossref
Crossref